Omnicell, Inc. provides automation and business analytics software solutions for medication and supply management in healthcare worldwide. The company operates through two segments, Automation and Analytics, and Medication Adherence. It offers Omnicell Automated Dispensing Cabinets, a dispensing system, which automates the management and dispensing of medications; SinglePointe, a software product that controls medications; AnywhereRN, a software which remotely queue medications from automated dispensing cabinets; Omnicell Analytics and Pandora Analytics reporting and data analytics tools; and Anesthesia Workstation that manages anesthesia supplies and medications. The company also provides XR2 Central Pharmacy System, a hospital pharmacy robotics system; Central and Satellite Pharmacy Manager, an automated pharmacy storage and retrieval system; Controlled Substance Management, a controlled substance inventory management system; OmniLinkRx, a prescription routing system; and WorkflowRx, an automated pharmacy storage, retrieval, and packaging system. In addition, it offers Omnicell Supply Management System, an automated dispensing system; Omnicell Tissue Center, which manages the chain of custody for bone and tissue specimens; OptiFlex MS that manages medical and surgical supplies; OptiFlex SS, a module for the perioperative areas; and OptiFlex CL, a module for the cardiac catheterization lab and other procedure areas. Further, the company provides IV Solutions; enterprise analytics and solutions; Omnicell Interface Software; Mach4 Pharma Systems Medimat, a robotic dispensing system; Omnicell SupplyX subscription software; RFID solutions; and consumable medication blister cards, packaging equipment, and ancillary products and services to institutional pharmacies. The company was formerly known as Omnicell Technologies, Inc. and changed its name to Omnicell, Inc. in 2001. Omnicell, Inc. was founded in 1992 and is headquartered in Mountain View, California.
Industry, Sector and Symbol
Stock Exchange NASDAQ
Industry Electronic computers
Sub-IndustryHealth Care Technology
SectorMedical
SymbolNASDAQ:OMCL
CUSIP68213N10
Phone650-251-6100
Debt
Debt-to-Equity Ratio0.33
Current Ratio1.68
Quick Ratio1.22
Price-To-Earnings
Trailing P/E Ratio304.17
Forward P/E Ratio39.93
P/E Growth2.5
Sales & Book Value
Annual Sales$716.16 million
Price / Sales2.99
Cash Flow$1.6149 per share
Price / Cash34.12
Book Value$13.64 per share
Price / Book4.04
Profitability
EPS (Most Recent Fiscal Year)$0.18
Net Income$20.60 million
Net Margins4.55%
Return on Equity4.11%
Return on Assets2.15%
Miscellaneous
Employees2,350
Outstanding Shares38,880,000
Market Cap$2,109.13
Omnicell (NASDAQ:OMCL) Frequently Asked Questions
What is Omnicell's stock symbol?
Omnicell trades on the NASDAQ under the ticker symbol "OMCL."
How were Omnicell's earnings last quarter?
Omnicell, Inc. (NASDAQ:OMCL) issued its quarterly earnings results on Thursday, April, 26th. The company reported $0.29 earnings per share (EPS) for the quarter, beating analysts' consensus estimates of $0.25 by $0.04. The company earned $182.60 million during the quarter, compared to analysts' expectations of $177.49 million. Omnicell had a net margin of 4.55% and a return on equity of 4.11%. Omnicell's revenue was up 22.9% on a year-over-year basis. During the same period last year, the company posted $0.06 EPS. View Omnicell's Earnings History.
When is Omnicell's next earnings date?
What guidance has Omnicell issued on next quarter's earnings?
Omnicell updated its FY18 earnings guidance on Thursday, April, 26th. The company provided earnings per share (EPS) guidance of $1.85-$2.05 for the period, compared to the Thomson Reuters consensus estimate of $1.97. The company issued revenue guidance of $780-$800 million, compared to the consensus revenue estimate of $790.31 million.Omnicell also updated its Q2 guidance to $0.36-$0.42 EPS.
What price target have analysts set for OMCL?
6 equities research analysts have issued 12 month target prices for Omnicell's shares. Their predictions range from $44.00 to $63.00. On average, they expect Omnicell's stock price to reach $56.00 in the next twelve months. This suggests a possible upside of 1.6% from the stock's current price. View Analyst Ratings for Omnicell.
What is the consensus analysts' recommendation for Omnicell?
6 Wall Street analysts have issued "buy," "hold," and "sell" ratings for Omnicell in the last year. There are currently 2 hold ratings and 4 buy ratings for the stock, resulting in a consensus recommendation of "Buy."
What are Wall Street analysts saying about Omnicell stock?
Here are some recent quotes from research analysts about Omnicell stock:
- 1. Cantor Fitzgerald analysts commented, "On Monday, April 2, CNBC.com reported that Walmart and perhaps Amazon were looking to acquire PillPack." (4/3/2018)
- 2. According to Zacks Investment Research, "Omnicell’s fourth-quarter 2017 performance was impressive with year-over-year increase in both earnings and revenues. Further, both of the company’s segments witnessed year-over-year growth. We are encouraged to note that the company is working on product innovation through R&D. The company is expected to gain from its recent launches and strategic partnerships. Its recent product launches include the XR2 Automated Central Pharmacy System and the IVX Workflow, IVX Workflow creates a significant technological advancement for sterile compounding workflow processes, enabling pharmacies to safely and efficiently compound and prepare IV doses.Also, improvement in margin is also encouraging. However, a tough competitive landscape acts as a dampener. Over the past month, Omnicell’s shares have been trading below the broader industry." (2/2/2018)
Who are some of Omnicell's key competitors?
Who are Omnicell's key executives?
Omnicell's management team includes the folowing people:
- Mr. Randall A. Lipps, Founder, Exec. Chairman, Pres & CEO (Age 61)
- Mr. Peter J. Kuipers, Exec. VP & CFO (Age 46)
- Mr. Daniel S. Johnston, Exec. VP, Chief Legal & Admin. Officer and Corp. Sec. (Age 54)
- Mr. Robin G. Seim, Pres of Global Automation & Medication Adherence (Age 58)
- Mr. Joseph Brian Spears, VP of Corp. Fin. & Chief Accounting Officer (Age 58)
Has Omnicell been receiving favorable news coverage?
News coverage about OMCL stock has trended somewhat positive on Friday, Accern reports. Accern ranks the sentiment of news coverage by analyzing more than 20 million news and blog sources. Accern ranks coverage of publicly-traded companies on a scale of negative one to one, with scores closest to one being the most favorable. Omnicell earned a daily sentiment score of 0.11 on Accern's scale. They also gave headlines about the company an impact score of 45.43 out of 100, meaning that recent news coverage is somewhat unlikely to have an impact on the company's share price in the next several days.
Who are Omnicell's major shareholders?
Omnicell's stock is owned by many different of institutional and retail investors. Top institutional investors include Conestoga Capital Advisors LLC (4.72%), Fisher Asset Management LLC (1.11%), Summit Creek Advisors LLC (0.61%), Scout Investments Inc. (0.42%), Pwmco LLC (0.40%) and West Coast Financial LLC (0.29%). Company insiders that own Omnicell stock include Dan S Johnston, Gary S Petersmeyer, J Christopher Drew, James T Judson, Jorge R Taborga, Nhat H Ngo, Peter J Kuipers, Randall A Lipps, Robin Gene Seim and Sara J White. View Institutional Ownership Trends for Omnicell.
Which institutional investors are selling Omnicell stock?
OMCL stock was sold by a variety of institutional investors in the last quarter, including Fisher Asset Management LLC, Scout Investments Inc., Municipal Employees Retirement System of Michigan, West Coast Financial LLC, Foundry Partners LLC and Dubuque Bank & Trust Co.. Company insiders that have sold Omnicell company stock in the last year include Dan S Johnston, Gary S Petersmeyer, J Christopher Drew, Jorge R Taborga, Nhat H Ngo, Peter J Kuipers, Randall A Lipps and Robin Gene Seim. View Insider Buying and Selling for Omnicell.
Which institutional investors are buying Omnicell stock?
OMCL stock was purchased by a variety of institutional investors in the last quarter, including Pwmco LLC, Rhenman & Partners Asset Management AB, Conestoga Capital Advisors LLC, Peregrine Capital Management LLC, Summit Creek Advisors LLC and Bank of Montreal Can. View Insider Buying and Selling for Omnicell.
How do I buy shares of Omnicell?
Shares of OMCL can be purchased through any online brokerage account. Popular online brokerages with access to the U.S. stock market include Vanguard Brokerage Services, TD Ameritrade, E*TRADE, Scottrade, Fidelity and Charles Schwab.
What is Omnicell's stock price today?
One share of OMCL stock can currently be purchased for approximately $55.10.
How big of a company is Omnicell?
Omnicell has a market capitalization of $2.11 billion and generates $716.16 million in revenue each year. The company earns $20.60 million in net income (profit) each year or $0.18 on an earnings per share basis. Omnicell employs 2,350 workers across the globe.
How can I contact Omnicell?
Omnicell's mailing address is 590 EAST MIDDLEFIELD ROAD, MOUNTAIN VIEW CA, 94043. The company can be reached via phone at 650-251-6100 or via email at [email protected]
MarketBeat Community Rating for Omnicell (NASDAQ OMCL)
MarketBeat's community ratings are surveys of what our community members think about Omnicell and other stocks. Vote "Outperform" if you believe OMCL will outperform the S&P 500 over the long term. Vote "Underperform" if you believe OMCL will underperform the S&P 500 over the long term. You may vote once every thirty days.
